SCHEMBL715898

SCHEMBL715898

Cc1ccc(NC(=O)Nc2cccc(F)c2)cc1Nc1nc(-c2cccnc2)cs1

nearest known ligand 0.63

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 1/20 0.63
CYP1A1 P04798 1/20 0.61
CYP1A2 P05177 1/20 0.61
CYP1B1 Q16678 1/20 0.61
MEN1 O00255 6/20 0.61
KMT2A Q03164 6/20 0.61
ABL1 P00519 7/20 0.60
BCR P11274 6/20 0.60
PDGFRB P09619 2/20 0.60
HDAC3 O15379 1/20 0.60
KDR P35968 1/20 0.60
HDAC4 P56524 1/20 0.60
HDAC1 Q13547 1/20 0.60
HDAC7 Q8WUI4 1/20 0.60
HDAC2 Q92769 1/20 0.60
HDAC10 Q969S8 1/20 0.60
HDAC11 Q96DB2 1/20 0.60
HDAC8 Q9BY41 1/20 0.60
HDAC6 Q9UBN7 1/20 0.60
HDAC9 Q9UKV0 1/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL717030 0.93 GAA (0.65) GAAMEN1KMT2AABL1BCR
SCHEMBL14286286 0.90 MEN1 (0.64) GAAMEN1KMT2AABL1BCR
SCHEMBL716826 0.89 ABL1 (0.68) GAAMEN1KMT2AABL1BCR
SCHEMBL5579274 0.89 GAA (0.67) GAAMEN1KMT2AABL1BCR
SCHEMBL717044 0.89 GAA (0.74) GAAMEN1KMT2AABL1BCR
SCHEMBL719497 0.88 RAB9A (0.62) GAAMEN1KMT2AABL1BCR
SCHEMBL718498 0.88 ABL1 (0.70) GAAMEN1KMT2AABL1BCR
SCHEMBL14319701 0.87 GAA (0.65) GAAMEN1KMT2AABL1BCR
SCHEMBL715934 0.87 GAA (0.65) GAAMEN1KMT2AABL1BCR
SCHEMBL717539 0.86 GAA (0.62) GAAMEN1KMT2AABL1BCR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100491374-C 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2009-05-27 CN claimed
US-20080255141-A1 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders AB SCIENCE 2008-10-16 US claimed
US-7423055-B2 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE (FR) 2008-09-09 US claimed
EP-1525200-B1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2007-10-10 EP claimed
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes AB SCIENCE 2007-02-08 US claimed
US-20050239852-A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2005-10-27 US claimed
CN-1684959-A 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2005-10-19 CN claimed
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE 2004-06-10 US claimed
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 US disclosed
US-8993573-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2015-03-31 US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 US disclosed
US-8835435-B2 2-(3-aminoaryl) amino-4-aryl-thiazoles and their use as c-kit inhibitors AB SCIENCE (FR) 2014-09-16 US disclosed
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS AB SCIENCE (FR) 2014-03-27 US disclosed
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS AB SCIENCE (FR) 2014-03-27 US disclosed
EP-1653934-A2 USE OF C-KIT INHIBITORS FOR TREATING TYPE II DIABETES AB Science (FR) 2006-05-10 EP disclosed
CN-1684959-A 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as C-KIT inhibitors AB SCIENCE (FR) 2005-10-19 CN disclosed
EP-1525200-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB Science (FR) 2005-04-27 EP disclosed
WO-2005016323-A2 USE OF C-KIT INHIBITORS FOR TREATING TYPE II DIABETES AB SCIENCE (FR) 2005-02-24 WO disclosed
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. AB SCIENCE 2004-06-10 US disclosed
WO-2004014903-A1 2-(3-AMINOARYL)AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITORS AB SCIENCE (FR) 2004-02-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040110810-A1 e.g., 2-(2-methyl-5-amino)phenyl-4-(3-pyridyl)-thiazole; c-kit inhibitors; treating cell proliferative, metabolic, allergic, and degenerative disorders. KIT, MAP3K2, CMA1 GAA 496/4885CYP1A1 2179/4885CYP1A2 3030/4885
US-20070032521-A1 Use of c-kit inhibitors for treating type II diabetes KIT, CPA3, CMA1 GAA 360/4885CYP1A1 3576/4885CYP1A2 2913/4885
US-20140088108-A1 2-(3-AMINOARYL) AMINO-4-ARYL-THIAZOLES AND THEIR USE AS C-KIT INHIBITIORS KIT, CHUK, CKS1B GAA 619/4885CYP1A1 1335/4885CYP1A2 1884/4885
US-20050239852-A1 2-(3-aminoaryl)amino-4-aryl-thiazoles and their use as c-kit inhibitors KIT, CHUK, MAP3K2 GAA 633/4885CYP1A1 1329/4885CYP1A2 1875/4885
US-20080255141-A1 Modulators of signal transduction mediated by certain native and/or mutant tyrosine kinases; antiproliferative, anticarcinogenic, antiallergen, and antiinflammatory agents; metabolic and neurodegenerative disorders KIT, MAP3K1, MAP3K6 GAA 421/4885CYP1A1 1716/4885CYP1A2 3074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.